Kardiovaskuläre Effekte inkretinbasierter Therapien

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Herz

• Publication date

  2012-03-21

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00059-012-3599-8PMID 22430284
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.

  2012cited by this paper
• Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury.

  2011cited by this paper
• Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats

  2011cited by this paper
• Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.

  2011cited by this paper
• Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury.

  2011cited by this paper
• Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.

  2011cited by this paper
• Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.

  2011cited by this paper
• Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes.

  2011cited by this paper
• Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level.

  2011cited by this paper
• Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy

  2011cited by this paper
• Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.

  2011cited by this paper
• RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

  2010cited by this paper
• GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats

  2010cited by this paper
• Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes

  2010cited by this paper
• Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice

  2010cited by this paper
• Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

  2010cited by this paper
• Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

  2010cited by this paper
• Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies

  2010cited by this paper
• The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

  2010cited by this paper
• Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

  2010cited by this paper
• Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A

  2010cited by this paper
• Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

  2010cited by this paper
• Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure.

  2010cited by this paper
• Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38&agr; MAP Kinase-Mediated, Nitric Oxide-Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy

  2010cited by this paper
• Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression.

  2010cited by this paper
• Myocardial fatty acid metabolism in health and disease.

  2010cited by this paper
• DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease

  2010cited by this paper
• A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.

  2009cited by this paper
• Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

  2009cited by this paper
• GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a β-Arrestin 1-mediated ERK1/2 Activation in Pancreatic β-Cells

  2009cited by this paper
• Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides.

  2009cited by this paper
• Intensive glucose control and macrovascular outcomes in type 2 diabetes

  2009cited by this paper
• Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.

  2009cited by this paper
• Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model

  2009cited by this paper
• Glucose control and vascular complications in veterans with type 2 diabetes.

  2009cited by this paper
• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• Preconditioning and postconditioning: underlying mechanisms and clinical application.

  2009cited by this paper
• Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

  2009cited by this paper
• Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database

  2009cited by this paper
• GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart.

  2009cited by this paper
• Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes.

  2008cited by this paper
• GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.

  2008cited by this paper
• Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat

  2008cited by this paper
• Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

  2008cited by this paper
• Images in clinical medicine. Paget's disease of the mandible.

  2008cited by this paper
• Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart.

  2008cited by this paper
• DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes.

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

  2008cited by this paper
• Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting.

  2007cited by this paper
• Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.

  2007cited by this paper
• Biology of incretins: GLP-1 and GIP.

  2007cited by this paper
• Myocardial Ischaemia-reperfusion Injury is Attenuated by Intact Glucagon Like Peptide-1 (GLP-1) in the In Vitro Rat Heart and may Involve the p70s6K Pathway

  2007cited by this paper
• Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

  2006cited by this paper
• Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

  2006cited by this paper
• Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

  2006cited by this paper
• Glucagon‐like peptide 1(GLP‐1) in biology and pathology

  2005cited by this paper
• Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism.

  2005cited by this paper
• Glucagon-Like Peptide-1 Limits Myocardial Stunning following Brief Coronary Occlusion and Reperfusion in Conscious Canines

  2005cited by this paper
• Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

  2005cited by this paper
• Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.

  2005cited by this paper
• Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

  2004cited by this paper
• Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy

  2004cited by this paper
• New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway.

  2004cited by this paper
• Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

  2004cited by this paper
• The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy.

  2004cited by this paper
• Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.

  2004cited by this paper
• Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.

  2003cited by this paper
• Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

  2003cited by this paper
• Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium.

  2003cited by this paper
• Cardiac function in mice lacking the glucagon-like peptide-1 receptor.

  2003cited by this paper
• GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.

  2002cited by this paper
• Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.

  2002cited by this paper
• Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat.

  2000cited by this paper
• Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats.

  1999cited by this paper
• Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats.

  1999cited by this paper
• A Review of Metabolic and Cardiovascular Effects of Oral Antidiabetic Agents: Beyond Glucose-Level Lowering

  1999cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor.

  1996cited by this paper
• Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

  1995cited by this paper
• Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable

  1993cited by this paper
• GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery.

  1993cited by this paper
• Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing.

  1986cited by this paper

• Diabetologie als fächerübergreifende interdisziplinäre Herausforderung

  2017cites this paper
• [Diabetology as an interdisciplinary challenge].

  2017cites this paper